ShanghaiMay 28, 2026 /PRNewswire/ — Innogen Pharma (Hong Kong Stock Exchange Stock Code: 02591), a biopharmaceutical company focused on the research, development, and commercialization of innovative drugs for metabolic diseases, announced that it will present data from the Phase IIb clinical study of Efsubaglutide Alfa in China at the 2026 American Diabetes Association (ADA) Scientific Sessions. The conference will be held from June 5 to 8, 2026, in New Orleans, USA.
Innogen Pharma’s presentations at the conference are as follows:
Poster on Efsubaglutide Alfa
Title: Efsubaglutide Alfa in Overweight or Obesity: Phase IIb ENLIGHT Study
English Title: Efsubaglutide Alfa in Overweight or Obesity: Phase IIb ENLIGHT Study
Abstract Number: 2636-P
Time: June 8, 2026, 12:30 PM (Central Time, USA)
Presenter: Dr. Qinghua Wang, Founder, Chairman, and CEO of Innogen Pharma
The top-line data from the Phase IIb ENLIGHT study of Innogen Pharma’s self-developed Efsubaglutide Alfa in Chinese overweight and obese patients met the primary endpoint. The study adopted a randomized, double-blind, placebo-controlled, multi-center design, enrolling 200 overweight and obese adult subjects without diabetes to evaluate the efficacy and safety of Efsubaglutide Alfa at doses ranging from 5 to 20 mg over 18 weeks of treatment. Results showed that body weight in all dose groups significantly decreased from baseline, outperforming the placebo group, with a positive dose-response relationship for weight loss. During the treatment period, patients in the Efsubaglutide Alfa group exhibited a continuous downward trend in body weight, with no plateau observed.
The study employed a concise yet aggressive dose titration regimen (escalating every 2 weeks, reaching the target dose of 20 mg within 6 weeks, covering both QW and Q2W administration routes). Results indicated that after 18 weeks of treatment, including the titration and maintenance periods, Efsubaglutide Alfa significantly reduced subjects’ body weight, with decreases of 10.58% and 9.70% in the QW and Q2W groups, respectively. Additionally, metabolic parameters such as waist circumference, visceral fat, and liver fat were significantly improved. Notably, the weight loss primarily consisted of fat rather than muscle, leading to a substantial 45.3% increase in the muscle-to-fat ratio; furthermore, liver fat content decreased significantly by 46.9%. In terms of safety, no hypoglycemic events occurred during the treatment period, and gastrointestinal adverse reactions were mostly mild to moderate, transient, and self-resolving.
Dr. Qinghua Wang noted: “The results of the Phase IIb clinical study of Efsubaglutide Alfa presented at this ADA Annual Meeting are highly encouraging. As an innovative long-acting agonist originating from China, this drug, through its unique molecular structure design, achieves both potent weight loss and ‘fat reduction with muscle preservation,’ offering significant differentiated core advantages, along with good tolerability and convenient dosing. This set of high-quality clinical data fully confirms the broad prospects of Efsubaglutide Alfa in obesity treatment and provides a strong scientific basis for the upcoming Phase III clinical studies. We will spare no effort to accelerate subsequent research, advancing this original Chinese achievement to benefit patients at home and abroad as soon as possible.”
This content is intended solely for conveying the company’s R&D progress and industry information for reference, and does not constitute any form of drug advertisement, medication advice, or efficacy commitment. Prescription drugs should be purchased with a physician’s prescription and used under a physician’s guidance.
About Innogen Pharma
Innogen Pharma (HK.2591), founded in 2014, is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative drugs for metabolic diseases. It boasts a wholly self-developed pipeline covering indications such as T1D, obesity, MASH, and AD, with global intellectual property rights and a global patent portfolio. The company’s core product, Efsubaglutide Alfa, is a self-developed next-generation human long-acting GLP-1 receptor agonist, which has been approved for marketing in Mainland China and Macau, China for the treatment of type 2 diabetes, and has been successfully included in the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2025). It is currently in the global development and registration phase, committed to providing better treatment options for patients worldwide. For more information, please visit: www.innogenpharm.com.